Z
300702
vs
S
Shanghai Composite
Over the past 12 months, Zhejiang Tianyu Pharmaceutical Co Ltd has underperformed Shanghai Composite, delivering a return of +9% compared to the Shanghai Composite's +23% growth.
Stocks Performance
300702 vs Shanghai Composite
Performance Gap
300702 vs Shanghai Composite
Performance By Year
300702 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Zhejiang Tianyu Pharmaceutical Co Ltd
Glance View
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of chemical raw materials and intermediates. The company is headquartered in Taizhou, Zhejiang and currently employs 4,991 full-time employees. The company went IPO on 2017-09-19. The firm operates three segments. The Pharmaceutical Intermediates segment include hypertension drugs raw materials, anti-asthma drugs raw materials and anticoagulant drugs raw materials. The Active Pharmaceutical Ingredients (API) segment is engaged in production of high blood pressure drug intermediates, anti-asthma drug intermediates and antiviral drug intermediates. The firm also operates Other segment. The firm sells its products to both domestic and international markets, including Europe, the United States, Japan, South Korea and so on.
